{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:23:54Z","timestamp":1790115834956,"version":"4.0.1"},"reference-count":113,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Beyond its typical synovio-entheseal manifestations, psoriatic arthritis (PsA) is a systemic immune-mediated disease that carries a substantial, independent risk of major adverse cardiovascular events (MACE). The complex interaction of chronic systemic inflammation, a high prevalence of traditional risk factors, and PsA treatment drugs results in this increased cardiovascular burden, which is commonly underestimated in cardiology practice. Adipokine balance, insulin signalling, and lipid metabolism are all impacted by cytokine-driven systemic inflammation, which promotes metabolic abnormalities and accelerated atherogenesis. PsA-specific therapy has a complex and significant effect on cardiovascular risk. While there is evidence that strong inflammation suppression with tumour necrosis factor-\u03b1 (TNF-\u03b1) inhibitors may reduce cardiovascular risk, some medications, such as Janus kinase (JAK) inhibitors, should be carefully considered due to potential side effects. In order to outline the epidemiology and pathophysiology of the PsA-cardiovascular risk nexus, this narrative review synthesises recent data. It also offers a critical framework for managing cardiovascular risk in this susceptible group, advocating for a multidisciplinary approach that incorporates strict management of both inflammation and traditional risk factors to lessen the excessive burden of MACE.<\/jats:p>","DOI":"10.3390\/ijms27104226","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:49:09Z","timestamp":1778572149000},"page":"4226","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Risk in Psoriatic Arthritis: Mechanisms, Risk Assessment, and Long-Term Management Implications"],"prefix":"10.3390","volume":"27","author":[{"given":"Stefan","family":"Totolici","sequence":"first","affiliation":[{"name":"Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana-Maria","family":"Vrabie","sequence":"additional","affiliation":[{"name":"Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-9149","authenticated-orcid":false,"given":"Catalin Adrian","family":"Buzea","sequence":"additional","affiliation":[{"name":"Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2683-3054","authenticated-orcid":false,"given":"Elisabeta","family":"Badila","sequence":"additional","affiliation":[{"name":"Cardiology Department, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1759720X21998279","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: A narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","article-title":"Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study","volume":"19","author":"Bengtsson","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","article-title":"Cardiometabolic comorbidities in RA and PsA: Lessons learned and future directions","volume":"15","author":"Ferguson","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Radi\u0107, M., Belan\u010di\u0107, A., \u0110oga\u0161, H., Vu\u010dkovi\u0107, M., Sener, Y.Z., Sener, S., Fajki\u0107, A., and Radi\u0107, J. (2025). Cardiometabolic Risk in Psoriatic Arthritis: A Hidden Burden of Inflammation and Metabolic Dysregulation. Metabolites, 15.","DOI":"10.3390\/metabo15030206"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Puig, L. (2018). Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010058"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/1756-185X.14603","article-title":"Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials","volume":"26","author":"Cai","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3899\/jrheum.170379","article-title":"Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: An international multicenter study","volume":"45","author":"Eder","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: A systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: A systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2010.02310.x","article-title":"Psoriasis is associated with clinically significant cardiovascular risk: A Danish nationwide cohort study","volume":"270","author":"Ahlehoff","year":"2011","journal-title":"J. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3899\/jrheum.160070","article-title":"Disease activity and increased risk of cardiovascular death among patients with psoriatic arthritis","volume":"43","author":"Juneblad","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/07853890.2015.1068950","article-title":"Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies","volume":"47","author":"Ambrosino","year":"2015","journal-title":"Ann. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s40744-024-00676-z","article-title":"Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort Study","volume":"11","author":"Triantafyllias","year":"2024","journal-title":"Rheumatol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: A multi-centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tsioufis, P., Theofilis, P., Tsioufis, K., and Tousoulis, D. (2022). The Impact of Cytokines in Coronary Atherosclerotic Plaque: Current Therapeutic Approaches. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415937"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Henein, M.Y., Vancheri, S., Longo, G., and Vancheri, F. (2022). The Role of Inflammation in Cardiovascular Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112906"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11883-021-00963-y","article-title":"Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics","volume":"23","author":"Weber","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s10067-022-06484-6","article-title":"Autonomic dysfunction and cardiovascular risk in psoriatic arthritis","volume":"42","author":"Gezer","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sajja, A.P., Joshi, A.A., Teague, H.L., Dey, A.K., and Mehta, N.N. (2018). Potential immunological links between psoriasis and cardiovascular disease. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01234"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1759720X241274537","DOI":"10.1177\/1759720X241274537","article-title":"Cardiovascular comorbidities in psoriatic arthritis: State of the art","volume":"16","author":"Dey","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Arida, A., Protogerou, A.D., Kitas, G.D., and Sfikakis, P.P. (2018). Systemic inflammatory response and atherosclerosis: The paradigm of chronic inflammatory rheumatic diseases. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071890"},{"key":"ref_28","first-page":"23","article-title":"Elevated serum levels of TNF-\u03b1 and IL-17 in psoriatic and rheumatoid arthritis","volume":"31","author":"Angelov","year":"2023","journal-title":"Rheumatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Boutet, M.A., Nerviani, A., Gallo Afflitto, G., and Pitzalis, C. (2018). Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020530"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chen, P., and Li, X. (2024). NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1430236"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lee, B.W., and Moon, S.J. (2023). Inflammatory Cytokines in Psoriatic Arthritis: Understanding Pathogenesis and Implications for Treatment. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202306.2029.v1"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2047487319886404","article-title":"The metabolic syndrome\u2013What is it and how should it be managed?","volume":"26","author":"Nilsson","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1007\/s10067-025-07637-z","article-title":"Prevalence of metabolic syndrome and its components in psoriatic arthritis compared with general population, cutaneous psoriasis, and other inflammatory arthropathies: A meta-analysis","volume":"44","author":"Andreasson","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/acr.24820","article-title":"All-Cause and Cause-Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta-Analysis","volume":"75","author":"Chaudhary","year":"2023","journal-title":"Arthritis Care Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and Psoriatic Arthritis: A Narrative Review","volume":"7","author":"Ogdie","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41584-025-01326-6","article-title":"The obesity\u2013inflammation axis in psoriatic disease: Mechanisms and therapeutic strategies","volume":"22","author":"Haberman","year":"2025","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Feij\u00f3o-Band\u00edn, S., Arag\u00f3n-Herrera, A., Mora\u00f1a-Fern\u00e1ndez, S., Anido-Varela, L., Taraz\u00f3n, E., Rosell\u00f3-Llet\u00ed, E., Portol\u00e9s, M., Moscoso, I., Gualillo, O., and Gonz\u00e1lez-Juanatey, J.R. (2020). Adipokines and inflammation: Focus on cardiovascular diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207711"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Landecho, M.F., Tuero, C., Valent\u00ed, V., Bilbao, I., de la Higuera, M., and Fr\u00fchbeck, G. (2019). Relevance of leptin and other adipokines in obesity-associated cardiovascular risk. Nutrients, 11.","DOI":"10.3390\/nu11112664"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: An interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/rheumatology\/kes242","article-title":"Obesity and psoriatic arthritis: From pathogenesis to clinical outcome and management","volume":"52","author":"Russolillo","year":"2013","journal-title":"Rheumatology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/1756-185X.14375","article-title":"Risk of incident type 2 diabetes in patients with psoriatic arthritis: A systematic review and meta-analysis of cohort studies","volume":"25","author":"Yuan","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e005352","DOI":"10.1136\/rmdopen-2024-005352","article-title":"The metabolic score for insulin resistance predicts the risk of cardiovascular disease in patients with psoriatic arthritis: Results from the 10-year prospective CARMA cohort","volume":"11","author":"Plaza","year":"2025","journal-title":"RMD Open"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Grygiel-G\u00f3rniak, B., and Skoczek, W. (2023). Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185814"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Szukiewicz, D. (2023). Molecular Mechanisms for the Vicious Cycle between Insulin Resistance and the Inflammatory Response in Obesity. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202305.1026.v1"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Acosta-Martinez, M., and Cabail, M.Z. (2022). The PI3K\/Akt Pathway in Meta-Inflammation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232315330"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacl.2018.03.091","article-title":"Identification of proresolving and inflammatory lipid mediators in human psoriasis","volume":"12","author":"Sorokin","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5114\/reum.2021.110610","article-title":"Patterns of dyslipidemia in young patients with seronegative spondyloarthropathies without cardiovascular diseases","volume":"59","author":"Ozdowska","year":"2021","journal-title":"Reumatologia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/ard.59.11.904","article-title":"Lipoproteins and their subfractions in psoriatic arthritis: Identification of an atherogenic profile with active joint disease","volume":"59","author":"Jones","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","article-title":"Metabolic Messengers: Tumour necrosis factor","volume":"3","author":"Sethi","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Piaserico, S., Orlando, G., and Messina, F. (2022). Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169063"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11906-024-01311-6","article-title":"Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysis","volume":"26","author":"Barozet","year":"2024","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Atzeni, F., La Corte, L., Cirillo, M., Giallanza, M., Galloway, J., and Rodr\u00edguez-Carrio, J. (2023). Metabolic Syndrome and Its Components Have a Different Presentation and Impact as Cardiovascular Risk Factors in Psoriatic and Rheumatoid Arthritis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12155031"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41569-023-00964-1","article-title":"Immune and inflammatory mechanisms in hypertension","volume":"21","author":"Guzik","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, H., and Dhalla, N.S. (2024). The Role of Pro-Inflammatory Cytokines in the Pathogenesis of Cardiovascular Disease. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021082"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e081860","DOI":"10.1136\/bmj-2024-081860","article-title":"Advances in the management of psoriatic arthritis in adults","volume":"387","author":"Kharouf","year":"2024","journal-title":"BMJ"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar4174","article-title":"Use of NSAIDs in treating patients with arthritis","volume":"15","author":"Crofford","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2018-213089","article-title":"Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis","volume":"77","author":"Dubreuil","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1759720X211027712","DOI":"10.1177\/1759720X211027712","article-title":"Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: A time-dependent Cox regression analysis","volume":"13","author":"Lam","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_62","first-page":"16911","article-title":"Prevalence of cardiovascular comorbidities in psoriatic arthritis: Relationship with clinical phenotype and treatment in a real-life study","volume":"135","author":"Nowakowski","year":"2025","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/joim.13505","article-title":"Lessons from 20 years with COX-2 inhibitors: Importance of dose\u2013response considerations and fair play in comparative trials","volume":"292","author":"Stiller","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1210\/en.2012-2045","article-title":"New insights into the anti-inflammatory mechanisms of glucocorticoids: An emerging role for glucocorticoid-receptor-mediated transactivation","volume":"154","author":"Vandevyver","year":"2013","journal-title":"Endocrinology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1093\/rheumatology\/keac129","article-title":"Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: A systematic review","volume":"61","author":"Vincken","year":"2022","journal-title":"Rheumatology"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Beaupere, C., Liboz, A., F\u00e8ve, B., Blondeau, B., and Guillemain, G. (2021). Molecular mechanisms of glucocorticoid-induced insulin resistance. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020623"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Pujades-Rodriguez, M., Morgan, A.W., Cubbon, R.M., and Wu, J. (2020). Dose-dependent oral glucocorticoid cardiovascular risks in people with immunemediated inflammatory diseases: A population-based cohort study. PLoS Med., 17.","DOI":"10.1101\/2020.03.11.20034157"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/gut.28.2.190","article-title":"Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species","volume":"28","author":"Miyachi","year":"1987","journal-title":"Gut"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: Mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E24579","DOI":"10.1097\/MD.0000000000024579","article-title":"Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis","volume":"100","author":"Sun","year":"2021","journal-title":"Medicine"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"152031","DOI":"10.1016\/j.semarthrit.2022.152031","article-title":"Methotrexate use reduces mortality risk in rheumatoid arthritis: A systematic review and meta-analysis of cohort studies","volume":"55","author":"Xu","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated with Changes in Blood Pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J. Clin. Rheumatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ahmed, S., Jacob, B., Carsons, S.E., De Leon, J., and Reiss, A.B. (2022). Treatment of cardiovascular disease in rheumatoid arthritis: A complex challenge with increased atherosclerotic risk. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010011"},{"key":"ref_76","first-page":"e82269","article-title":"Cardiovascular Outcomes of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Review of the Current Evidence","volume":"17","author":"Sunkara","year":"2025","journal-title":"Cureus"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/1756-185X.12986","article-title":"Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study","volume":"20","author":"Tam","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103889","DOI":"10.1016\/j.autrev.2025.103889","article-title":"Cardiovascular risk in psoriatic arthritis: How can we manage it?","volume":"24","author":"Atzeni","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The Effect of TNF Inhibitors on Cardiovascular Events in Psoriasis and Psoriatic Arthritis: An Updated Meta-Analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2025.03.055","article-title":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study","volume":"93","author":"Song","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40744-025-00753-x","article-title":"The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations","volume":"12","author":"Avouac","year":"2025","journal-title":"Rheumatol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_83","first-page":"e60980","article-title":"The Impact of Interleukin-17 Inhibitors on Major Adverse Cardiovascular Events in Psoriasis or Psoriatic Arthritis Patients Naive to Biologic Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"16","author":"Ni","year":"2024","journal-title":"Cureus"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lin, T.-L., Fan, Y.-H., Fan, K.-S., Juan, C.-K., Chen, Y.-J., and Wu, C.-Y. (2025). Cardiovascular disease risk in patients with psoriasis receiving biologics targeting TNF-\u03b1, IL-12\/23, IL-17, and IL-23: A population-based retrospective cohort study. PLoS Med., 22.","DOI":"10.1371\/journal.pmed.1004591"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e15419","DOI":"10.1111\/1756-185X.15419","article-title":"JAK Inhibitors and Cardiovascular Disease in Psoriatic Arthritis: Friends or Foe?","volume":"27","author":"Shi","year":"2024","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.clinthera.2025.01.005","article-title":"Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis","volume":"47","author":"Zhao","year":"2025","journal-title":"Clin. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: A nationwide cohort study","volume":"61","author":"Penso","year":"2022","journal-title":"Rheumatology"},{"key":"ref_92","first-page":"678","article-title":"Cardiometabolic Effects of Apremilast in Patients With Psoriatic Arthritis: A Prospective Cohort Study","volume":"52","author":"Hansildaar","year":"2025","journal-title":"J. Rheumatol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Guerra, P., Di Cesare, A., Rosi, E., Scandagli, I., Silvi, G., Nunziati, G., and Prignano, F. (2024). Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience. Life, 14.","DOI":"10.3390\/life14030395"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/acr.22536","article-title":"Cardiovascular risk profile at the onset of psoriatic arthritis: A population-based cohort study","volume":"67","author":"Ernste","year":"2015","journal-title":"Arthritis Care Res."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Navarini, L., Margiotta, D.P.E., Caso, F., Currado, D., Tasso, M., Angeletti, S., Ciccozzi, M., Scarpa, R., Afeltra, A., and Costa, L. (2018). Performances of five risk algorithms in predicting cardiovascular events in patients with Psoriatic Arthritis: An Italian bicentric study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205506"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1093\/rheumatology\/kead610","article-title":"The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: An observational validation study using the Clinical Practice Research Datalink","volume":"63","author":"Hughes","year":"2024","journal-title":"Rheumatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10067-025-07325-y","article-title":"External validation of the accuracy of cardiovascular risk prediction tools in psoriatic disease: A UK Biobank study","volume":"44","author":"Hughes","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Yagensky, V., and Schirmer, M. (2022). Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study. Front. Med., 9.","DOI":"10.3389\/fmed.2022.786776"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/art.42694","article-title":"Derivation and Internal Validation of a Disease-Specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis","volume":"76","author":"Colaco","year":"2024","journal-title":"Arthritis Rheumatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ad.2022.04.013","article-title":"Performance of Coronary Artery Calcium Testing in Patients With Severe Psoriasis: Risk Assessment and Reclassification Potential in a Low Cardiovascular Risk Population","volume":"113","year":"2022","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40257-025-00996-y","article-title":"Cardiovascular Imaging in Psoriasis: A Critical Review of Current Evidence, Techniques, and Therapeutic Implications","volume":"27","author":"Tartaglia","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/24755303251337020","article-title":"Practical Recommendations on Cardiovascular Risk Evaluation in Patients With Psoriasis and Psoriatic Arthritis for Dermatologists, Rheumatologists, and Primary Care Physicians by the Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network","volume":"10","author":"Sheth","year":"2025","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43166-022-00128-y","article-title":"Psoriatic arthritis treatment to the target: A consensus, evidence-based clinical practice recommendations for the management of psoriatic arthritis and its concomitant clinical manifestations","volume":"49","author":"GadAllah","year":"2022","journal-title":"Egypt. Rheumatol. Rehabil."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2021-222020","article-title":"2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases","volume":"82","author":"Gwinnutt","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations","volume":"81","author":"Usman","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e24314","DOI":"10.1002\/clc.24314","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of Randomized-Controlled Trials","volume":"47","author":"Hosseinpour","year":"2024","journal-title":"Clin. Cardiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/rheumatology\/kez677","article-title":"A machine-learning approach to cardiovascular risk prediction in psoriatic arthritis","volume":"59","author":"Navarini","year":"2020","journal-title":"Rheumatology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1007\/s13555-025-01529-5","article-title":"Biologic Therapies and Major Cardiovascular Events in Psoriasis: Updated Systematic Review and Meta-analysis","volume":"15","author":"Mangkorntongsakul","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s10067-025-07418-8","article-title":"AI in psoriatic disease (\u201cPsAI\u201d): Current insights and future directions","volume":"44","author":"Venerito","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1759720X251357188","DOI":"10.1177\/1759720X251357188","article-title":"Cardio-rheumatology: Integrated care and the opportunities for personalized medicine","volume":"17","author":"Ciosek","year":"2025","journal-title":"Ther. Adv. Musculoskelet. Dis."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4226\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:57:01Z","timestamp":1778572621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":113,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104226"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104226","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]}}}